A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test the efficacy and safety of a revolutionary new treatment using nasal cells. The Griffith University trial has been three decades in the making and involves taking olfactory ensheathing cells, which are specialised cells involved in our sense of smell, from the nose as they have numerous therapeutic properties for repairing and regenerating nerves. Read full a rticle here .
Tel Aviv University is preparing the first human spinal cord implant trial, offering hope for people paralyzed by injury.
Researchers have identified the neurons responsible for boosting the intensity of breathing when organs need more oxygen, for example, during exercise or at high altitudes. This discovery, published in Cell Reports , unveils a potential new target for treatments seeking to restore normal breathing functions in people who have suffered a spinal cord injury. Read full article here.
A Swiss research center is trying to use innovative technology to help restore bodily functions for paralyzed patients—and even help Parkinson's patients walk smoothly again. "60 Minutes" is the most successful television broadcast in history. Offering hard-hitting investigative reports, interviews, feature segments and profiles of people in the news, the broadcast began in 1968 and is still a hit, over 50 seasons later, regularly making Nielsen's Top 10. See full video here
Dear Colleague, Welcome to the Open Data Commons for Spinal Cord Injury (ODC-SCI)! The ODC-SCI was established in 2017 as a dedicated data sharing portal and repository for the field of SCI. Through the ODC-SCI, you can share data with your colleagues in a protected space and publish data to the public with a DOI. The ODC-SCI complies with the FAIR data principles to ensure that SCI data is Findable, Accessible, Interoperable and Reusable. With the growth of this community we hope to expand the amount of data sharing and promote transparency and reproducibility for our common goal to find a cure for SCI, and provide a means for the SCI community to meet increasing funder and journal data sharing requirements. Read full article here .
This news release constitutes a “designated news release” for the purposes of NervGen’s prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024.
China’s neural bypass technology restores nerve function, challenging U.S. dominance in neurotechnology.
